Arsanis begins dosing patients in Phase II trial of ASN100 to prevent S. aureus pneumonia

Bio-pharmaceutical company Arsanis has begun dosing patients in a Phase II clinical trial of ASN100 to treat Staphylococcus aureus (S.aureus) pneumonia in high-risk, mechanically ventilated patients.
Source: Drug Development Technology - Category: Pharmaceuticals Source Type: news